About: Epelsiban

An Entity of Type: chemical substance, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

Epelsiban (INN, USAN, code name GSK-557,296-B) is an orally bioavailable drug which acts as a selective and potent oxytocin receptor antagonist (Ki = 0.13 nM). It was initially developed by GlaxoSmithKline (GSK) for the treatment of premature ejaculation in men and then as an agent to enhance embryo or blastocyst implantation in women undergoing embryo or blastocyst transfer associated with in vitro fertilization (IVF)., and was also investigated for use in the treatment of adenomyosis.

Property	Value
dbo:abstract	Epelsiban (INN, USAN, code name GSK-557,296-B) is an orally bioavailable drug which acts as a selective and potent oxytocin receptor antagonist (Ki = 0.13 nM). It was initially developed by GlaxoSmithKline (GSK) for the treatment of premature ejaculation in men and then as an agent to enhance embryo or blastocyst implantation in women undergoing embryo or blastocyst transfer associated with in vitro fertilization (IVF)., and was also investigated for use in the treatment of adenomyosis. (en)
dbo:casNumber	1159097-48-9 (besylate) 872599-83-2
dbo:chEMBL	2037511
dbo:drugbank	DB11934
dbo:fdaUniiCode	T2EZ19HX73
dbo:kegg	D10117
dbo:pubchem	11634973
dbo:thumbnail	wiki-commons:Special:FilePath/Epelsiban_chemical_structure_1.svg?width=300
dbo:wikiPageID	33556050 (xsd:integer)
dbo:wikiPageLength	14743 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID	1059782877 (xsd:integer)
dbo:wikiPageWikiLink	dbr:Benign_prostatic_hyperplasia dbr:Barusiban dbr:Blood-brain_barrier dbr:Cytochrome_P450 dbr:Ugi_reaction dbr:In_vitro dbr:Intracerebroventricular_injection dbr:Isozymes dbc:Indanes dbr:GlaxoSmithKline dbr:Morpholine dbr:Homochiral dbr:Embryo dbr:Receptor_antagonist dbr:Premature_ejaculation dbr:Adenomyosis dbr:Dissociation_constant dbr:Oxytocin_receptor dbr:2,5-diketopiperazine dbr:Central_nervous_system dbc:Diketopiperazines dbc:Morpholines dbc:Pyridines dbc:Oxytocin_receptor_antagonists dbr:International_Nonproprietary_Name dbr:Atosiban dbr:L-368,899 dbr:L-371,257 dbr:Blastocyst dbr:Pharmacokinetic dbr:In_vitro_fertilisation dbr:Carboxybenzyl dbr:United_States_Adopted_Name dbr:In_silico dbr:Structure–activity_relationship dbr:Vasopressin_receptor dbr:Retosiban dbr:Epimerisation dbr:Microsomes dbr:Besylate dbr:Carbonyl_diimidazole dbr:Diastereoisomers dbr:Stereoselective_synthesis dbr:File:Discovery_of_Epelsiban.svg dbr:File:Synthesis_of_Epelsiban.svg
dbp:atcPrefix	None (en)
dbp:c	30 (xsd:integer)
dbp:casNumber	872599 (xsd:integer)
dbp:casSupplemental	1159097 (xsd:integer)
dbp:chembl	2037511 (xsd:integer)
dbp:chemspiderid	9809717 (xsd:integer)
dbp:drugbank	DB11934 (en)
dbp:h	38 (xsd:integer)
dbp:iupacName	-3 (xsd:integer)
dbp:kegg	D10117 (en)
dbp:legalStatus	Non-regulated (en)
dbp:n	4 (xsd:integer)
dbp:o	4 (xsd:integer)
dbp:pubchem	11634973 (xsd:integer)
dbp:smiles	CC[C@H][C@@H]1CN[C@@H]C4CC5=CC=CC=C5C4 (en)
dbp:stdinchi	1 (xsd:integer)
dbp:stdinchikey	UWHCWRQFNKUYCG-QUZACWSFSA-N (en)
dbp:unii	T2EZ19HX73 (en)
dbp:width	250 (xsd:integer)
dbp:wikiPageUsesTemplate	dbt:Drugbox dbt:Reflist dbt:Fdacite dbt:Keggcite dbt:Drugs_for_erectile_dysfunction_and_PE dbt:Oxytocin_and_vasopressin_receptor_modulators
dcterms:subject	dbc:Indanes dbc:Diketopiperazines dbc:Morpholines dbc:Pyridines dbc:Oxytocin_receptor_antagonists
gold:hypernym	dbr:Drug
rdf:type	owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 yago:Abstraction100002137 yago:Base114618253 yago:Chemical114806838 yago:Compound114818238 yago:Hydrocarbon114911057 yago:Indene114824906 yago:Material114580897 yago:Matter100020827 yago:OrganicCompound114727670 yago:Part113809207 yago:PhysicalEntity100001930 yago:Pyridine114692510 yago:Relation100031921 yago:WikicatIndenes dbo:Drug yago:Substance100019613 yago:WikicatPyridines
rdfs:comment	Epelsiban (INN, USAN, code name GSK-557,296-B) is an orally bioavailable drug which acts as a selective and potent oxytocin receptor antagonist (Ki = 0.13 nM). It was initially developed by GlaxoSmithKline (GSK) for the treatment of premature ejaculation in men and then as an agent to enhance embryo or blastocyst implantation in women undergoing embryo or blastocyst transfer associated with in vitro fertilization (IVF)., and was also investigated for use in the treatment of adenomyosis. (en)
rdfs:label	Epelsiban (en)
owl:sameAs	freebase:Epelsiban yago-res:Epelsiban wikidata:Epelsiban dbpedia-vi:Epelsiban https://global.dbpedia.org/id/4jXMd
prov:wasDerivedFrom	wikipedia-en:Epelsiban?oldid=1059782877&ns=0
foaf:depiction	wiki-commons:Special:FilePath/Discovery_of_Epelsiban.svg wiki-commons:Special:FilePath/Epelsiban_chemical_structure_1.svg wiki-commons:Special:FilePath/Synthesis_of_Epelsiban.svg
foaf:isPrimaryTopicOf	wikipedia-en:Epelsiban
is dbo:wikiPageRedirects of	dbr:GSK-557,296 dbr:GSK-557,296-B dbr:GSK-557,296B dbr:GSK-557296 dbr:GSK-557296-B dbr:GSK-557296B dbr:GSK557296 dbr:GSK557296B dbr:GSK_557,296 dbr:GSK_557296 dbr:GSK_557296_B
is dbo:wikiPageWikiLink of	dbr:Barusiban dbr:2,5-Diketopiperazine dbr:Oxytocin_receptor dbr:L-368,899 dbr:L-371,257 dbr:Retosiban dbr:GSK-557,296 dbr:GSK-557,296-B dbr:GSK-557,296B dbr:GSK-557296 dbr:GSK-557296-B dbr:GSK-557296B dbr:GSK557296 dbr:GSK557296B dbr:GSK_557,296 dbr:GSK_557296 dbr:GSK_557296_B
is foaf:primaryTopic of	wikipedia-en:Epelsiban